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1. Introduction1
Pulmonary fungal infections are disease of bronchopulmo-
nary caused by fungal, including primary and secondary 
pulmonary fungal infections. Fungal spores are inhaled 
into the lungs and the disease is called the primary pul-
monary fungal infection. In other parts of the body, fungal 
infection is caused by the lymphatic or blood to the lungs, 
which is called secondary pulmonary fungal infection. 
Pulmonary fungal infection is very common in clinical 
setting, especially severe patients in ICU, because of the 
low immunity, large amount of antibiotics, intubation and 
other invasive treatment, therefore treatment of fungal in-
fection is more difficult, but also increased the risk of the 
development of opportunity diseases in patients [1−2]. 
Prevention of fungal infection of patients with severe pul-
monary infection in ICU, in order to reduce the degree of 
infection. In this paper, the characteristics and preventive 
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effect of patients in ICU with severe pulmonary fungal in-
fection were analyzed.
2. Materials and methods
2.1. Clinical data
Selected patients in ICU of our hospital from January 2012 
to December 2012 diagnosis by sputum culture confirmed 
severe pulmonary fungal infections in 120 cases as the 
research object. Approval by the hospital ethics commit-
tee and patient informed consent by clinicians, according 
to the diagnostic criteria of reference the 2011 American 
Thoracic Society in adult pulmonary and critical care pa-
tients with fungal infection treatment guidelines for the in-
troduction [3]. According to the clinical application of an-
tibiotics in patients, the study group was form by 68 cases, 
which 38 male and 30 female, and aged from 52 to 83 years 
old, with average (22 ± 5.3) years old. From there, 16 cases 
of severe craniocerebral injury, 5 cases of cerebral infarc-
tion, 8 cases of pulmonary infection, 15 cases of pulmo-
nary edema, 2 cases of acute respiratory distress syndrome 
(66.3 cases). The control group was form with 52 cases, 
which 31 male and 21 female, and aged from 54−82 years 
old, with the average (65.8 ± 4.8) years old. From a total 52 
cases, there were 12 cases of severe brain injury, 4 cases of 
cerebral infarction, 15 cases of pulmonary infection, 6 cas-
es of pulmonary edema, 13 cases of obstructive pulmonary 
emphysema, 2 cases of acute respiratory distress syndrome. 
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There was no significant difference in gender, age and basic 
diseases between the two groups (p > 0.05).
2.2. Method
The study group was found to be associated with adverse 
symptoms of fungal infection in clinical implementation 
of preventive antibiotics, the control group was found in 
symptoms and diagnosis of fungal infection after symp-
tomatic application of antibiotics. Including types of anti-
biotics: fluconazole, amphotericin B and voriconazole. At 
the same time according to the test results of sputum fun-
gal infection characteristics.
2.3. Efficacy evaluation criteria
Fungal infection in patients with therapeutic effect by 
clinical symptoms improvement (asthma, cough, expecto-
ration) and signs improve (pulmonary rales, temperature 
changes), image results (lung shadow disappeared) com-
prehensive evaluation. The results divided into recovery, 
improvement, and invalid, while the treatment efficiency = 
(cure and improvement)/number of research cases × 100%.
2.4. Statistical processing
Data were processed and analyzed by software SPSS 18.0, 
and data were analyzed by chi square test. When p < 0.05, 
the difference was statistically significant.
3. Results
3.1. Comparison of curative effect
Clinical efficacy in two groups of patients in ICU with 
severe pulmonary fungal infection, wherein study group 
was significantly higher than control group, and the dif-
ference was statistically significant (p < 0.05). From there, 
1 patients from the study group were significantly worse; 
whereas for control group, there were 6 patients treated 
with invalid, and 4 cases from there were worsen and 2 
cases were died. 
Table 1. Comparison of treatment effect of two groups of pa-
tients with pulmonary fungal infection (cases %).
Group Cases Cure Improving Invalid Treatment 
efficiency (%)
Research group 68 30 37 1 98.52
Control group 52 20 26 6 88.46
x2 - - - - 5.437
p - - - - < 0.05
3.2. Fungal infection characteristics
The results of sputum culture in 120 cases of severe pul-
monary fungal infection with patients in ICU, as shown in 
Table 2, the proportion of Candida albicans was the high-
est, which was significantly higher than Candida glabrata 
and Candida parapsilosis, and the difference between data 
was statistically significant (x2 = 147.635, 161.186, p < 0.01).
Table 2. 120 cases of fungal infection in patients with pulmo-
nary fungal infection.
Fungal type Cases Proportion (%)
Candida albicans 104 86.67
Candida glabrata 10 8.33
Candida parapsolosis 6 5.00
Total 120 100
3.3. Risk factors analysis
In this study, more than 2 kinds long-term use of corticos-
teroids and immunosuppressive agents in patients were 
72 cases, which accounted for 60% from the total num-
ber. Among them, 26 patients had long-term application 
of glucocorticoids, which accounted for 21.67%, and 33 
patients had long-term application of immunosuppres-
sive agents, accounted for 27.50%. Besides that, 45 patients 
with low serum protein, accounted for 37.50%, 32 cases of 
low lymphocytes, accounted for 26.67% cases, and patients 
with tracheostomy was 28 cases, accounted for 31.67% 
cases. Moreover, 38 patients that hospitalize more than one 
week, accounted for 31.67%, and there were 80 cases of pa-
tients that using two or more broad-spectrum antifungal 
drug which hospitalized more than 1 week, accounted for 
66.67%. Specific results are shown in Table 3.
Table 3. 120 risk factors of pulmonary fungal infection in pa-
tients.
Risk factors Cases Proportion (%)
Long term application of glucocorticoids 26 21.67
Long term application of 
immunosuppressive agents
33 27.50
Low serum protein 45 37.50
Low lymphocytes 32 26.67
Hospitalized more than 1 weeks 38 31.67
Tracheal intubation and tracheotomy 28 31.67
Using two or more broad-spectrum and 
highly effective drug, hospitalized more 
than 1 weeks
80 66.67
Two factors above 72 60.00
4. Discussion
ICU patients with serious illness, which their body’s im-
mune function defects, and easy encounter with lung in-
fection that trigger by various factors, especially in most 
patients with invasive treatment, such as catheter place-
ment in vivo, which provides favorable conditions for fun-
gal infection [4]. The clinical symptoms and signs are not 
specific to pulmonary fungal infection, such as cough, ex-
pectoration, fever, psychiatric symptom, which is similar 
with most basic diseases and common bacterial infection. 
Hence it not easy to discover on time, and delayed the 
diagnosis, which greatly affected the effectiveness of the 
medication and treatment [5‒6]. Pulmonary fungal infec-
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tion further reduce patients’ immunity, causing tissue inju-
ry, and even worsen the primary diseases, induce all sorts 
of complication; therefore, timely treatment to improve the 
patients symptoms and improve the quality of life was sig-
nificance important.
In this study, 1 patients from the study group were de-
teriorate, and 6 patients from control group were treated 
with invalid, from there 2 patients died of heart failure, 
and 4 patients had worse condition, therefore effective rate 
of study group was significantly higher than that of control 
group, and the difference was statistically significant (p < 
0.05). It is not difficult to see that implementation of pre-
ventive antibiotics in study group can effectively reduce the 
clinical symptoms, has a good clinical application effect. It 
is not difficult to see that the proportion of Candida albi-
cans was the highest in this study. The highest proportion 
of Candida albicans in Table 2 was significantly higher than 
that of Candida glabrata and Candida parapsilosis. The dif-
ference between the data was statistically significant (x2 = 
147.635, 161.186, p < 0.01). Therefore, in the prophylactic 
use of drug, it should pay attention to the corresponding 
symptoms caused by different microbes, to increase the ef-
fectiveness and efficiency of the treatment. 
Prophylactic drugs purpose was used before unknown 
clinical diagnosis of patients with infection, and the appli-
cation of antibiotics for anti-inflammatory treatment. Once 
the patient carry a pathogenic fungus, drugs can quickly 
play a role in the treatment, to achieve the purpose of early 
treatment and recovery. In this group of patients, the use 
of prophylactic medicine in clinical treatment which make 
the effective rate significantly higher than control group of 
patients with fungal infection, suggesting that the clini-
cal application of prophylactic antibiotics is beneficial to 
improve the treatment of ICU patients with severe pul-
monary fungal infection. It not only reduce the patient’s 
pain, but also conducive to the prevention of early com-
plications and primary diseases. But it is worth to point-
ing out that the abuse of antibiotics has become the most 
discussed topic, hence the application of sputum culture 
confirmed the infection was caused by relative microbes 
and the application of symptomatic medication will more 
conducive and avoid the misuse of drugs. Because pre-
ventive medicine is beneficial to improve the treatment 
effect of pulmonary fungal infection, hence it should 
further investigation of the characteristics of pulmonary 
fungal infection, so as to facilitate the usage of prophylac-
tic drugs, to avoid drug abuse. In addition should avoid 
the long-term use of antibiotic, to prevent the develop of 
drug’s resistant.
Candida albicans, Candida glabrata and Candida parap-
silosiswere are the main pathogenic microbes that induce 
severe pulmonary fungal infection in ICU. Fluconazole is 
a broad-spectrum antifungal drug that use for the treat-
ment of infection It has a good inhibitory effect of com-
mon fungal infection and better effect in term of oral drug 
absorption. For fasting oral medication, the absorption 
rate achieving 90% and not easy to be affected by diet, H2 
receptor blockers and anti-acid drugs. It subjected to re-
nal excretion and having minimum side effect. Ampho-
tericin B is a polyene antifungal medication, but the side 
effects of the drug are relatively large, which the admin-
istration prone to the adverse reactions such as nausea 
and vomiting, chills, headache, anemia, and white blood 
cells decreased. Administration of the drug should be cau-
tious where medication attention to patients with signs of 
change and timely evaluate the effect.
In conclusion, the treatment effect of prophylactic anti-
microbials drugs for patients in ICU with severe pulmo-
nary fungal infection can improve the therapeutic effect of 
antifungal, and accelerate the speed of disease remission. 
Candida albicans causing the major infection and the clini-
cal use of the antimicrobials drugs should be rational to 
prevent the drug abuse. 
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